

Healthy demand outlook; cost pressures remain a concern

- Higher pre-season growth in RAC CMs reflects strong inventory build-ups by brands, despite higher channel inventory, reflects optimism
- Globally elevated memory (DRAMs/NANDs) weighed on smartphones; challenges to continue. Dixon's backward integration on track
- Roll-forward to Mar-28EPS, cut multiples modestly to reflect demand uncertainty amid cost pressures. maintain ratings

Vineet Shanker
 Research Analyst
 Amey Tupe
 Research Associate
 research@bobcaps.in

RAC contract manufacturers reported strong growth, with improving utilisation driving profitable growth: During Q3, Amber, PGEL and Epack reported strong growth of 27%/81%/14% YoY, respectively. The growth was driven by higher outsourcing by brands, increased wallet shares and new client additions; while demand at the brand level was supported by channel stocking ahead of the BEE transition and cost inflation. Improving utilisation also supported profitable growth, following a weak Q2. This resulted in a sharp sequential margin expansion of ~3ppt for Amber and PGEL, although margins saw a marginal YoY compression.

Higher pre-season growth for RAC contract manufacturers reflects strong inventory build-up: We believe the strong growth across RAC contract manufacturers indicates improved demand expectations and proactive supply-chain readiness by brands, especially in the context of BEE transition and rising input costs. As per management commentary, industry inventory is estimated at ~4.0–4.5mn units, equivalent to ~25% of annual end-demand. This suggests brands are constructive on inventory normalisation in the upcoming season.

Elevated memory prices led to slowdown in smartphone volume: Dixon reported 5% YoY revenue growth in its Mobile division (-27% QoQ), with the sequential decline led by lower handset volumes, particularly in the mid segment, amid higher memory chip prices (DRAM/NAND). We expect memory prices to remain elevated due to global capacity constraints.

Backward integration, supported by policy tailwinds, remains on track: Syrma, Amber and Dixon are progressing on their backward integration plans through bare PCB capacity and mobile component manufacturing (including display and camera modules) under the ECMS scheme. Their planned capacity expansions also appear to be on track.

We roll forward our TP to Mar-28E EPS: We have modestly lowered multiples to reflect rising cost pressures in the industry, while maintaining our ratings across the coverage universe.

Recommendation snapshot

Ticker	Price	Target	Rating
AMBER IN	7,873	9,060	BUY
DIXON IN	10,029	14,200	BUY
EPACK IN	238	320	BUY
PGEL IN	609	610	HOLD
SYRMA IN	762	820	HOLD

Price & Target in Rupees | Price as of 6 Mar 2026



Fig 1 – Key takeaways from management commentaries of peers

Category	Dixon	Amber	PGEL	EPACK	Syrma
Demand	Demand impacted by high memory prices and affordability pressure in mass smartphones.	Q3 revenue grew 38% YoY, driven by strong growth in CD (+30% YoY) and Electronics (+79% YoY). Demand was supported by channel filling ahead of BEE transition and commodity cost inflation.	Strong recovery led by RAC and washing machines, with continued market share gains and higher outsourcing by brands. Growth is partly supported by channel pre-buying ahead of BEE transition, indicating demand not fully end-consumption driven.	Revenue grew 14% YoY, demand recovery and strong execution. Growth increasingly driven by diversification (washing machines, components, SDA).	Broad-based growth across verticals. Exports were the key demand driver with exports, supporting mix improvement and scale benefits.
Margins	EBITDA margin stable at ~3.9%, with mobile margins ~3.5-3.6% including PLI (~50-60 bps). Increase in memory prices is pass-through.	EBITDA margin expanded to ~8.4% (+90 bps YoY), led by strong improvement in Electronics margin. Input cost pressures (CCL, copper, gold) persist, with pass-through lag of ~1-1.5 quarters.	Margin contracted 50bps YoY due to input cost inflation and selective customer support. Raw material inflation (copper, aluminium) largely passed through with a 10-30-day lag.	Margin improved 100 bps YoY due to operating leverage and better mix. Margins supported by strong non-AC contribution, though PAT impacted by higher depreciation and interest.	Margin expansion was sharp on export-led mix + operating leverage, with EBITDA margin ~12.6% (elevated vs normalised guidance). Management indicated ~10% blended EBITDA margin as a more sustainable level over time.
Demand Outlook (Going ahead)	Medium-term smartphone volumes guided at ~60-65 mn units annually. Exports scaling to ~Rs 55-60 bn in FY26, with strong OEM traction. Demand recovery expected from Q1 FY27 as channel inventory normalises.	RAC industry expected to be flattish in FY26, but Amber guiding 13-15% growth on wallet share gains and client additions. Electronics expected to sustain growth with double-digit margins by FY27.	FY26 revenue guided at Rs 57-58 bn, supported by strong Q4 seasonality and order book. Demand recovery expected in FY27, driven by inventory normalisation.	Demand visibility improving into Q4FY26 with expected inventory normalisation and BEE-led replacement cycle. Industry expected to recover to ~15-20% growth in CY26 with a strong summer outlook.	Momentum expected to remain healthy with continued ramp-up in export-linked industrial, med-tech and auto programs; management confidence supported by secular, multi-vertical demand.
Key Risks	Memory price inflation continues to impact demand, especially in entry/mid segments. PLI uncertainty poses ~50-60 bps margin risk if not extended. Delays in Vivo JV and component ramp-up may cause execution and margin volatility (next 5-8 months).	Margin pressure in PCB segment due to elevated CCL/gold prices and execution risks in scaling new verticals.	High channel inventory (~4.5-5 mn RAC units) could delay demand normalisation. Q3 growth was partly driven by pre-buying which could risk of demand normalization in Q4.	AC demand still weak and relies on summer recovery and inventory normalisation. Execution risk in scaling new categories and component integration.	Q3 margins were unusually strong - risk of mean reversion toward ~10% guided level as mix/utilisation normalises.

Source: Company, BOBCAPS Research

Fig 2 – Capacity expansion plans of EMS companies

Dixon	Amber	PGEL	EPACK	Syrma
Capex remains focused on smartphone and notebook component localisation (Rs 15-16bn).	Building full-stack EMS/PCB ecosystem via Ascent, Korea Circuit JV and Shogini acquisition (~4.5 lakh sq m capacity).	Large capex of Rs 7-7.5 bn across refrigerators (~Rs 3 bn), washing machines, AC and new campuses.	Focused on diversification + backward integration + ODM scaling across appliances and components.	Bare PCB backward integration on track.
Rs 11-12 bn for display modules (HKC JV). Display module capacity - Phase 1, nearing completion, will have a capacity of 24mn units. Phase 2 will scale to 55mn units.	Large capex underway: Korea Circuit JV (~Rs 12 bn) + land acquisition (Jewar 100 acres) for Ascent circuit.	Building multi-location manufacturing hubs (North, West, South) for scale and integration.	Capex of ~Rs 2.5 bn planned (12-18 months) towards washing machines, components and new facilities.	Phase 1 capex of Rs 3.6-4.0bn, with total multi-phase PCB capex of Rs 15bn till FY30
Scaling camera modules to ~180-200mn units and will be investing Rs 2.5-3.0bn in Q-tech JV				
Rs 0.5-0.6 bn for mechanical enclosures				
Rs 0.5 bn for optical transceivers, while battery investments remain under evaluation				
Expanding large-scale capacity (Noida ~1 mn sq ft) + strong push into IT hardware & exports.				

Source: Company, BOBCAPS Research

Fig 3 – Amber / PGEL outperformed; Dixon reported muted growth on lower demand for smartphones

B2C	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	9MFY26	9MFY25	YoY (%)
Revenue								
Dixon	1,06,716	1,04,537	2	1,48,550	(28)	3,83,623	2,85,676	34
Amber	29,428	21,333	38	16,470	79	80,390	62,193	29
PGEL	14,121	9,677	46	6,554	115	35,713	29,597	21
Epack	4,278	3,768	14	2,133	101	13,034	15,276	(15)
EBITDA								
Dixon	4,145	3,905	6	5,613	(26)	14,582	10,648	37
EBITDA margin	3.9	3.7	15bps	3.8	10bps	3.8	3.7	7bps
Amber	2,461	1,587	55	913	170	5,941	4,686	27
EBITDA margin	8	7	92bps	6	282bps	7	8	(15bps)
PGEL	1,169	852	37	301	288	2,682	2,722	(1)
EBITDA margin	8	9	(52bps)	5	368bps	8	9	(169bps)
Epack	317	241	31	5	5800	869	854	2
EBITDA margin	7	6	101bps	0	716bps	7	6	107bps
EBIT								
Dixon	3,154	3,159	0	4,650	(32)	11,701	8,697	35
EBIT margin %	3.0	3.0	(7bps)	3.1	(17bps)	3.1	3.0	1bps
Amber	1,549	1,000	55	210	636	3,708	2,983	24
EBIT margin %	5.3	4.7	58bps	1.3	398bps	4.6	4.8	(18bps)
PGEL	949	688	38	84	1023	2,038	2,253	(10)
EBIT margin %	6.7	7.1	(39bps)	1.3	543bps	5.7	7.6	(191bps)
Epack	181	120	51	(130)	(239)	470	504	(7)
EBIT margin %	4.2	3.2	105bps	(6.1)	NA	3.6	3.3	31bps

Source: Company, BOBCAPS Research

Fig 4 – Syrma outperformed with strong growth and margin expansion

B2B	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	9MFY26	9MFY25	YoY (%)
Revenue								
Syrma	12,642	8,692	45	11,459	10	33,540	28,618	17
Kaynes	8,040	6,612	22	9,062	(11)	23,837	17,373	37
Avalon	4,175	2,809	49	3,825	9	11,233	7,553	49
EBITDA								
Syrma	1,594	791	102	1,152	38	3,613	1,946	86
EBITDA margin	13	9	351bps	10	255bps	11	7	397bps
Kaynes	1,193	940	27	1,480	(19)	3,804	2,431	56
EBITDA margin	15	14	62bps	16	(149bps)	16	14	197bps
Avalon	480	346	39	386	24	1,165	691	69
EBITDA margin	11	12	(82bps)	10	141bps	10	9	122bps
EBIT								
Syrma	1,391	588	136	934	49	2,986	1,403	113
EBIT margin %	11.0	6.8	424bps	8.1	285bps	8.9	4.9	400bps
Kaynes	989	832	19	1,314	(25)	3,277	2,153	52
EBIT margin %	12.3	12.6	(28bps)	14.5	(220bps)	13.7	12.4	135bps
Avalon	400	273	47	297	35	912	483	89
EBIT margin %	9.6	9.7	(14bps)	7.8	182bps	8.1	6.4	172bps

Source: Company, BOBCAPS Research

Valuation

We have modestly cut the 1YF multiples for our EMS coverage to factor in higher near-term uncertainty amid the rising industry cost pressures, including elevated DRAM/NAND prices for Dixon, higher copper/aluminium prices, BEE transition-related costs, rupee depreciation, and potential freight inflation due to geopolitical challenges. Although these costs are largely pass-through, with a lag, we believe they could weigh on the demand and increase quarterly volatility, especially in smartphones and air conditioners.

We roll forward our valuation to Mar-28E EPS with no change in ratings. Amber remains our top pick in the EMS space.

Fig 5 – TP revision from roll-forward to Mar-28EPS for our EMS coverage

Company	CMP	Old Rating	New Rating	Old TP (Dec-26TP)	New TP (Mar-27TP)	Old Target PE (x)	New Target PE (x)	FY25-28E CAGR (%)			P/E				EV/EBITDA			
								Revenue	EBITDA	PAT	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E
Dixon	10,151	BUY	BUY	14,500	14,200	50	45	28	30	20	95	44	48	32	41	32	25	18
Amber	7,926	BUY	BUY	8,700	9,060	42	40	27	31	48	110	90	51	35	37	30	21	16
Syrma	773	HOLD	HOLD	840	820	35	32	33	38	42	80	48	40	30	43	29	24	17
PGEL	616	HOLD	HOLD	630	610	40	36	19	20	18	61	62	50	36	35	33	26	20
Epack	240	BUY	BUY	340	320	25	20	20	30	40	42	114	32	15	17	18	11	8

Source: Company, BOBCAPS Research

Stock performance

Fig 6 – AMBER



Fig 7 – DIXON




Fig 8 – EPACK





Fig 9 – PGEL



Fig 10 – SYRMA



Source: NSE

Financials – AMBER

Income Statement

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Total revenue	67,293	99,730	1,24,936	1,59,610	2,02,942
EBITDA	4,919	7,634	9,318	13,142	17,355
Depreciation	1,865	2,283	3,152	3,850	4,798
EBIT	3,054	5,351	6,166	9,292	12,556
Net interest inc./(exp.)	(1,670)	(2,087)	(2,784)	(2,535)	(2,160)
Other inc./(exp.)	553	736	1,400	1,100	700
Exceptional items	0	0	0	0	0
EBT	1,937	3,999	4,782	7,857	11,096
Income taxes	519	1,188	1,181	1,978	2,793
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	(23)	(300)	(250)	(150)	(100)
Reported net profit	1,329	2,436	3,085	5,464	7,938
Adjustments	0	0	0	0	0
Adjusted net profit	1,329	2,436	3,085	5,464	7,938

Balance Sheet

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Accounts payables	21,671	31,703	39,706	50,725	64,497
Other current liabilities	3,525	4,051	6,722	8,587	10,918
Provisions	0	0	0	0	0
Debt funds	14,332	19,400	17,400	16,900	14,400
Other liabilities	5,761	6,268	6,534	6,800	7,065
Equity capital	337	338	351	351	351
Reserves & surplus	20,307	22,520	35,592	41,056	48,994
Shareholders' fund	20,644	22,858	35,944	41,408	49,345
Total liab. and equities	65,932	84,281	1,06,305	1,24,420	1,46,226
Cash and cash eq.	6,913	7,268	8,728	4,928	7,563
Accounts receivables	15,693	17,501	22,591	30,610	38,920
Inventories	8,408	16,551	25,672	28,424	36,140
Other current assets	2,531	5,160	6,465	8,259	10,501
Investments	0	0	0	0	0
Net fixed assets	20,919	22,840	23,839	31,989	35,191
CWIP	244	1,151	5,000	6,000	3,500
Intangible assets	7,997	8,384	8,484	8,584	8,684
Deferred tax assets, net	0	0	0	0	0
Other assets	3,226	5,426	5,526	5,626	5,726
Total assets	65,932	84,281	1,06,305	1,24,420	1,46,226

Cash Flows

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Cash flow from operations	9,648	7,109	1,394	9,634	10,570
Capital expenditures	(3,977)	(5,556)	(8,000)	(13,000)	(5,500)
Change in investments	(2,625)	(2,580)	(100)	(100)	(100)
Other investing cash flows	(3,743)	(1,394)	(100)	(100)	(100)
Cash flow from investing	(10,345)	(9,529)	(8,200)	(13,200)	(5,700)
Equities issued/Others	0	1	13	0	0
Debt raised/repaid	352	1,259	(2,000)	(500)	(2,500)
Interest expenses	0	0	0	0	0
Dividends paid	(1,567)	1,969	10,253	266	266
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(1,216)	3,229	8,266	(234)	(2,234)
Chg in cash & cash eq.	(1,913)	809	1,460	(3,800)	2,635
Closing cash & cash eq.	6,913	7,268	8,728	4,928	7,563

Per Share

Y/E 31 Mar (Rs)	FY24A	FY25A	FY26E	FY27E	FY28E
Reported EPS	39.4	72.3	87.8	155.4	225.8
Adjusted EPS	39.4	72.3	87.8	155.4	225.8
Dividend per share	0.0	0.0	0.0	0.0	0.0
Book value per share	612.7	678.4	1,022.6	1,178.1	1,403.9

Valuations Ratios

Y/E 31 Mar (x)	FY24A	FY25A	FY26E	FY27E	FY28E
EV/Sales	3.9	2.7	2.1	1.7	1.3
EV/EBITDA	53.9	34.7	28.5	20.2	15.3
Adjusted P/E	199.6	108.9	89.7	50.6	34.9
P/BV	12.8	11.6	7.7	6.7	5.6

DuPont Analysis

Y/E 31 Mar (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Tax burden (Net profit/PBT)	68.6	60.9	64.5	69.5	71.5
Interest burden (PBT/EBIT)	63.4	74.7	77.6	84.6	88.4
EBIT margin (EBIT/Revenue)	4.5	5.4	4.9	5.8	6.2
Asset turnover (Rev./Avg TA)	3.2	4.4	5.2	5.0	5.8
Leverage (Avg TA/Avg Equity)	1.1	1.1	0.8	0.8	0.8
Adjusted ROAE	6.7	11.2	10.5	14.1	17.5

Ratio Analysis

Y/E 31 Mar	FY24A	FY25A	FY26E	FY27E	FY28E
YoY growth (%)					
Revenue	(2.9)	48.2	25.3	27.8	27.1
EBITDA	17.7	55.2	22.1	41.0	32.1
Adjusted EPS	(15.5)	83.3	21.4	77.1	45.3
Profitability & Return ratios (%)					
EBITDA margin	7.3	7.7	7.5	8.2	8.6
EBIT margin	4.5	5.4	4.9	5.8	6.2
Adjusted profit margin	2.0	2.4	2.5	3.4	3.9
Adjusted ROAE	6.7	11.2	10.5	14.1	17.5
ROCE	7.5	10.0	10.8	13.0	15.4
Working capital days (days)					
Receivables	85	64	66	70	70
Inventory	46	61	75	65	65
Payables	118	116	116	116	116
Ratios (x)					
Gross asset turnover	2.6	3.3	3.6	3.7	3.9
Current ratio	1.0	1.0	1.2	1.1	1.1
Net interest coverage ratio	1.8	2.6	2.2	3.7	5.8
Adjusted debt/equity	0.7	0.8	0.5	0.4	0.3

Source: Company, BOBCAPS Research | Note: TA = Total Assets

Financials – DIXON

Income Statement

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Total revenue	1,76,909	3,88,601	4,88,562	6,39,128	8,11,202
EBITDA	6,976	15,076	19,166	24,345	33,338
Depreciation	1,619	2,810	3,796	4,478	5,607
EBIT	5,358	12,266	15,369	19,867	27,731
Net interest inc./(exp.)	(747)	(1,544)	(1,428)	(934)	(330)
Other inc./(exp.)	226	202	6,500	500	700
Exceptional items	0	0	0	0	0
EBT	4,836	10,924	20,441	19,433	28,101
Income taxes	1,189	3,372	5,151	4,897	7,081
Extraordinary items	0	(4,600)	0	0	0
Min. int./Inc. from assoc.	102	174	243	316	411
Reported net profit	3,678	10,955	13,683	12,632	18,767
Adjustments	0	(4,600)	0	0	0
Adjusted net profit	3,678	6,356	13,683	12,632	18,767

Balance Sheet

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Accounts payables	40,598	1,08,837	1,36,530	1,57,593	2,00,022
Other current liabilities	6,074	15,395	19,355	19,261	19,780
Provisions	0	0	0	0	0
Debt funds	4,890	6,710	6,210	3,460	1,223
Other liabilities	1,404	6,626	8,476	10,696	13,360
Equity capital	120	121	121	121	121
Reserves & surplus	16,829	29,982	43,545	56,058	74,706
Shareholders' fund	16,949	30,102	43,666	56,179	74,826
Total liab. and equities	69,914	1,67,669	2,14,236	2,47,188	3,09,211
Cash and cash eq.	2,087	2,635	9,023	(12,260)	(8,717)
Accounts receivables	23,179	69,655	88,343	1,17,319	1,48,905
Inventories	16,950	39,924	53,541	70,041	88,899
Other current assets	6,147	18,730	17,401	20,137	23,780
Investments	0	0	0	0	0
Net fixed assets	16,367	21,091	29,856	37,377	42,271
CWIP	643	2,561	3,000	1,500	1,000
Intangible assets	3,635	6,655	6,655	6,655	6,655
Deferred tax assets, net	0	0	0	0	0
Other assets	906	6,418	6,418	6,418	6,418
Total assets	69,914	1,67,669	2,14,236	2,47,188	3,09,211

Cash Flows

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Cash flow from operations	5,843	11,498	18,156	(10,133)	13,234
Capital expenditures	(5,686)	(8,956)	(13,000)	(10,500)	(10,000)
Change in investments	344	(3,210)	0	0	0
Other investing cash flows	33	(123)	0	0	0
Cash flow from investing	(5,309)	(12,289)	(13,000)	(10,500)	(10,000)
Equities issued/Others	469	1,399	0	0	0
Debt raised/repaid	(276)	583	(500)	(2,750)	(2,237)
Interest expenses	0	0	0	0	0
Dividends paid	(893)	(2,248)	1,731	2,101	2,545
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(700)	(266)	1,231	(649)	308
Chg in cash & cash eq.	(166)	(1,057)	6,387	(21,282)	3,542
Closing cash & cash eq.	2,087	2,635	9,023	(12,260)	(8,717)

Per Share

Y/E 31 Mar (Rs)	FY24A	FY25A	FY26E	FY27E	FY28E
Reported EPS	61.8	184.0	229.8	212.1	315.1
Adjusted EPS	61.8	106.7	229.8	212.1	315.1
Dividend per share	2.0	8.0	2.0	2.0	2.0
Book value per share	284.6	505.5	733.3	943.4	1,256.5

Valuations Ratios

Y/E 31 Mar (x)	FY24A	FY25A	FY26E	FY27E	FY28E
EV/Sales	3.4	1.5	1.2	0.9	0.7
EV/EBITDA	85.6	39.6	31.2	24.5	17.9
Adjusted P/E	162.4	94.0	43.6	47.3	31.8
P/BV	35.2	19.8	13.7	10.6	8.0

DuPont Analysis

Y/E 31 Mar (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Tax burden (Net profit/PBT)	76.0	58.2	66.9	65.0	66.8
Interest burden (PBT/EBIT)	90.3	89.1	133.0	97.8	101.3
EBIT margin (EBIT/Revenue)	3.0	3.2	3.1	3.1	3.4
Asset turnover (Rev./Avg TA)	10.8	18.4	16.4	17.1	19.2
Leverage (Avg TA/Avg Equity)	1.1	0.9	0.8	0.7	0.6
Adjusted ROAE	24.7	27.0	37.1	25.3	28.7

Ratio Analysis

Y/E 31 Mar	FY24A	FY25A	FY26E	FY27E	FY28E
YoY growth (%)					
Revenue	45.1	119.7	25.7	30.8	26.9
EBITDA	36.1	116.1	27.1	27.0	36.9
Adjusted EPS	43.9	72.8	115.3	(7.7)	48.6
Profitability & Return ratios (%)					
EBITDA margin	3.9	3.9	3.9	3.8	4.1
EBIT margin	3.0	3.2	3.1	3.1	3.4
Adjusted profit margin	2.1	1.6	2.8	2.0	2.3
Adjusted ROAE	24.7	27.0	37.1	25.3	28.7
ROCE	21.5	23.4	30.2	21.4	24.4
Working capital days (days)					
Receivables	48	65	66	67	67
Inventory	35	37	40	40	40
Payables	84	102	102	90	90
Ratios (x)					
Gross asset turnover	10.5	15.6	14.0	13.5	13.9
Current ratio	1.0	1.0	1.1	1.1	1.1
Net interest coverage ratio	7.2	7.9	10.8	21.3	84.0
Adjusted debt/equity	0.3	0.2	0.1	0.1	0.0

Source: Company, BOBCAPS Research | Note: TA = Total Assets

Financials – EPACK

Income Statement

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Total revenue	14,196	21,709	21,155	28,529	37,129
EBITDA	1,162	1,577	1,473	2,387	3,450
Depreciation	355	474	611	844	964
EBIT	807	1,103	862	1,543	2,486
Net interest inc./(exp.)	(300)	(329)	(552)	(542)	(462)
Other inc./(exp.)	89	211	160	250	250
Exceptional items	0	0	0	0	0
EBT	507	774	310	1,002	2,025
Income taxes	138	193	78	251	508
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	(15)	(30)	(30)	(25)	0
Reported net profit	354	551	202	725	1,517
Adjustments	0	0	0	0	0
Adjusted net profit	354	551	202	725	1,517

Balance Sheet

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Accounts payables	4,156	5,389	5,506	7,425	9,155
Other current liabilities	673	968	944	1,272	1,656
Provisions	0	0	0	0	0
Debt funds	3,314	3,697	5,197	4,697	4,197
Other liabilities	613	556	556	556	556
Equity capital	958	960	960	960	960
Reserves & surplus	7,964	8,559	8,761	9,486	11,003
Shareholders' fund	8,922	9,518	9,721	10,446	11,962
Total liab. and equities	17,678	20,128	21,923	24,396	27,526
Cash and cash eq.	1,071	442	(1,217)	(489)	(694)
Accounts receivables	2,124	2,980	3,478	3,908	5,086
Inventories	3,782	5,807	6,376	7,035	9,155
Other current assets	3,028	845	345	345	345
Investments	0	0	1,000	1,000	1,000
Net fixed assets	5,362	5,450	7,421	8,577	8,614
CWIP	266	582	500	0	0
Intangible assets	6	12	12	12	12
Deferred tax assets, net	0	0	0	0	0
Other assets	2,039	4,008	4,008	4,008	4,008
Total assets	17,678	20,128	21,923	24,396	27,526

Cash Flows

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Cash flow from operations	2,570	313	340	2,728	1,295
Capital expenditures	(1,501)	(1,117)	(2,500)	(1,500)	(1,000)
Change in investments	(52)	(144)	(1,000)	0	0
Other investing cash flows	(2,213)	315	0	0	0
Cash flow from investing	(3,766)	(946)	(3,500)	(1,500)	(1,000)
Equities issued/Others	4,000	26	0	0	0
Debt raised/repaid	(1,773)	167	1,500	(500)	(500)
Interest expenses	0	0	0	0	0
Dividends paid	0	0	0	0	0
Other financing cash flows	(561)	(486)	0	0	0
Cash flow from financing	1,666	(294)	1,500	(500)	(500)
Chg in cash & cash eq.	469	(927)	(1,660)	728	(205)
Closing cash & cash eq.	1,071	442	(1,217)	(489)	(694)

Per Share

Y/E 31 Mar (Rs)	FY24A	FY25A	FY26E	FY27E	FY28E
Reported EPS	3.7	5.7	2.1	7.6	15.8
Adjusted EPS	3.7	5.7	2.1	7.6	15.8
Dividend per share	0.0	0.0	0.0	0.0	0.0
Book value per share	93.1	99.2	101.3	108.8	124.6

Valuations Ratios

Y/E 31 Mar (x)	FY24A	FY25A	FY26E	FY27E	FY28E
EV/Sales	1.4	0.9	0.9	0.6	0.5
EV/EBITDA	16.9	12.8	12.2	7.1	5.2
Adjusted P/E	64.5	41.5	113.0	31.5	15.1
P/BV	2.6	2.4	2.4	2.2	1.9

DuPont Analysis

Y/E 31 Mar (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Tax burden (Net profit/PBT)	69.8	71.2	65.2	72.4	74.9
Interest burden (PBT/EBIT)	62.8	70.2	36.0	64.9	81.4
EBIT margin (EBIT/Revenue)	5.7	5.1	4.1	5.4	6.7
Asset turnover (Rev./Avg TA)	264.7	398.3	285.1	332.6	431.1
Leverage (Avg TA/Avg Equity)	0.9	0.6	0.8	0.9	0.8
Adjusted ROAE	5.9	6.0	2.1	7.2	13.5

Ratio Analysis

Y/E 31 Mar	FY24A	FY25A	FY26E	FY27E	FY28E
YoY growth (%)					
Revenue	(7.8)	52.9	(2.5)	34.9	30.1
EBITDA	13.3	35.8	(6.6)	62.1	44.5
Adjusted EPS	(39.8)	55.6	(63.3)	258.6	109.1
Profitability & Return ratios (%)					
EBITDA margin	8.2	7.3	7.0	8.4	9.3
EBIT margin	5.7	5.1	4.1	5.4	6.7
Adjusted profit margin	2.5	2.5	1.0	2.5	4.1
Adjusted ROAE	5.9	6.0	2.1	7.2	13.5
ROCE	6.9	8.0	5.3	8.8	13.1
Working capital days (days)					
Receivables	55	50	60	50	50
Inventory	97	98	110	90	90
Payables	107	91	95	95	90
Ratios (x)					
Gross asset turnover	2.7	3.2	2.6	2.7	3.1
Current ratio	1.3	1.0	1.0	1.0	1.1
Net interest coverage ratio	2.1	2.0	1.2	1.9	3.5
Adjusted debt/equity	0.4	0.4	0.5	0.4	0.4

Source: Company, BOBCAPS Research | Note: TA = Total Assets

Financials – PGEL

Income Statement

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Total revenue	27,465	48,695	55,643	66,704	81,649
EBITDA	2,618	4,841	5,124	6,425	8,369
Depreciation	466	656	869	1,469	1,895
EBIT	2,152	4,184	4,255	4,956	6,475
Net interest inc./(exp.)	(387)	(537)	(604)	(592)	(530)
Other inc./(exp.)	130	351	527	444	489
Exceptional items	0	0	0	0	0
EBT	1,765	3,647	3,650	4,364	5,945
Income taxes	395	738	869	895	1,219
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	(21)	(31)	40	50	60
Reported net profit	1,349	2,878	2,822	3,519	4,786
Adjustments	0	0	0	0	0
Adjusted net profit	1,349	2,878	2,822	3,519	4,786

Balance Sheet

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Accounts payables	6,464	13,744	15,705	18,827	23,045
Other current liabilities	1,435	4,802	5,487	6,577	8,051
Provisions	0	0	0	0	0
Debt funds	3,606	3,019	4,519	3,769	3,019
Other liabilities	1,194	1,361	1,361	1,361	1,361
Equity capital	260	283	283	283	283
Reserves & surplus	10,121	27,999	30,821	34,340	39,126
Shareholders' fund	10,381	28,282	31,104	34,623	39,409
Total liab. and equities	23,080	51,208	58,176	65,157	74,885
Cash and cash eq.	1,824	9,797	3,953	2,561	6,913
Accounts receivables	5,530	9,804	12,196	14,620	17,896
Inventories	5,434	13,162	16,769	20,103	20,133
Other current assets	1,269	4,775	5,456	6,540	8,006
Investments	0	0	0	0	0
Net fixed assets	7,813	11,343	12,210	19,741	20,347
CWIP	632	736	6,000	0	0
Intangible assets	34	42	42	42	42
Deferred tax assets, net	0	0	0	0	0
Other assets	543	1,549	1,549	1,549	1,549
Total assets	23,080	51,208	58,176	65,157	74,885

Cash Flows

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Cash flow from operations	1,863	(766)	(344)	2,358	7,601
Capital expenditures	(2,258)	(4,872)	(7,000)	(3,000)	(2,500)
Change in investments	(88)	1	0	0	0
Other investing cash flows	(1,646)	(7,142)	0	0	0
Cash flow from investing	(3,992)	(12,014)	(7,000)	(3,000)	(2,500)
Equities issued/Others	0	14,899	0	0	0
Debt raised/repaid	(2,091)	(728)	1,500	(750)	(750)
Interest expenses	0	0	0	0	0
Dividends paid	0	0	0	0	0
Other financing cash flows	4,434	(881)	0	0	0
Cash flow from financing	2,344	13,290	1,500	(750)	(750)
Chg in cash & cash eq.	215	510	(5,844)	(1,392)	4,351
Closing cash & cash eq.	1,824	9,797	3,953	2,561	6,913

Per Share

Y/E 31 Mar (Rs)	FY24A	FY25A	FY26E	FY27E	FY28E
Reported EPS	5.2	10.2	10.0	12.4	16.9
Adjusted EPS	5.2	10.2	10.0	12.4	16.9
Dividend per share	0.0	0.0	0.0	0.0	0.0
Book value per share	39.9	99.9	109.9	122.3	139.2

Valuations Ratios

Y/E 31 Mar (x)	FY24A	FY25A	FY26E	FY27E	FY28E
EV/Sales	6.2	3.6	3.2	2.6	2.1
EV/EBITDA	64.6	36.1	34.3	26.7	20.8
Adjusted P/E	117.5	59.9	61.1	49.0	36.0
P/BV	15.3	6.1	5.5	5.0	4.4

DuPont Analysis

Y/E 31 Mar (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Tax burden (Net profit/PBT)	76.4	78.9	77.3	80.6	80.5
Interest burden (PBT/EBIT)	82.0	87.2	85.8	88.1	91.8
EBIT margin (EBIT/Revenue)	7.8	8.6	7.6	7.4	7.9
Asset turnover (Rev./Avg TA)	351.5	429.3	455.7	337.9	401.3
Leverage (Avg TA/Avg Equity)	1.1	0.6	0.4	0.6	0.5
Adjusted ROAE	18.8	14.9	9.5	10.7	12.9

Ratio Analysis

Y/E 31 Mar	FY24A	FY25A	FY26E	FY27E	FY28E
YoY growth (%)					
Revenue	27.2	77.3	14.3	19.9	20.0
EBITDA	48.6	84.9	5.8	25.4	30.3
Adjusted EPS	52.2	96.1	(2.0)	24.7	36.0
Profitability & Return ratios (%)					
EBITDA margin	9.5	9.9	9.2	9.6	10.3
EBIT margin	7.8	8.6	7.6	7.4	7.9
Adjusted profit margin	2.8	2.8	5.2	4.2	4.3
Adjusted ROAE	18.8	14.9	9.5	10.7	12.9
ROCE	16.6	21.3	12.9	11.7	13.8
Working capital days (days)					
Receivables	73	73	80	80	80
Inventory	72	99	110	110	90
Payables	86	103	103	103	103
Ratios (x)					
Gross asset turnover	3.4	4.2	3.8	3.4	3.2
Current ratio	1.5	1.9	1.6	1.6	1.6
Net interest coverage ratio	4.2	4.7	3.8	4.8	6.4
Adjusted debt/equity	0.3	0.1	0.1	0.1	0.1

Source: Company, BOBCAPS Research | Note: TA = Total Assets

Financials – SYRMA

Income Statement

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Total revenue	31,541	37,867	46,807	64,851	89,964
EBITDA	2,023	3,233	4,901	5,947	8,448
Depreciation	515	751	870	916	1,423
EBIT	1,508	2,482	4,030	5,032	7,026
Net interest inc./(exp.)	(413)	(585)	(462)	(678)	(888)
Other inc./(exp.)	586	494	500	600	500
Exceptional items	0	0	0	0	0
EBT	1,681	2,392	4,069	4,953	6,637
Income taxes	421	526	952	1,247	1,671
Extraordinary items	14	21	0	0	0
Min. int./Inc. from assoc.	0	0	0	25	50
Reported net profit	1,076	1,699	3,067	3,681	4,909
Adjustments	14	21	0	0	0
Adjusted net profit	1,090	1,720	3,067	3,681	4,909

Balance Sheet

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Accounts payables	12,232	15,744	19,236	26,651	36,972
Other current liabilities	1,028	812	912	1,012	1,112
Provisions	0	0	0	0	0
Debt funds	6,299	6,646	3,846	4,846	6,346
Other liabilities	1,210	1,345	1,345	1,345	1,345
Equity capital	1,774	1,780	1,923	1,923	1,923
Reserves & surplus	14,352	15,719	28,354	31,747	36,368
Shareholders' fund	16,126	17,500	30,277	33,670	38,291
Total liab. and equities	36,896	42,047	55,617	67,525	84,066
Cash and cash eq.	1,210	3,942	8,402	4,934	6,556
Accounts receivables	9,301	14,775	19,236	24,874	32,042
Inventories	10,043	8,219	11,542	15,102	20,951
Other current assets	2,207	2,474	1,539	2,132	2,958
Investments	64	180	2,530	2,530	2,530
Net fixed assets	6,674	8,030	8,660	14,244	13,821
CWIP	3,029	719	0	0	1,500
Intangible assets	4,144	3,460	3,460	3,460	3,460
Deferred tax assets, net	0	0	0	0	0
Other assets	223	248	248	248	248
Total assets	36,897	42,047	55,617	67,525	84,066

Cash Flows

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Cash flow from operations	(1,136)	1,765	680	2,320	2,911
Capital expenditures	(3,377)	(2,452)	(1,500)	(6,500)	(1,000)
Change in investments	(2,293)	626	(2,350)	0	0
Other investing cash flows	5,388	774	719	0	(1,500)
Cash flow from investing	(282)	(1,052)	(3,131)	(6,500)	(2,500)
Equities issued/Others	(80)	(125)	143	0	0
Debt raised/repaid	2,320	330	(2,800)	1,000	1,500
Interest expenses	0	0	0	0	0
Dividends paid	(694)	(912)	9,568	(288)	(288)
Other financing cash flows	0	0	0	0	0
Cash flow from financing	1,547	(707)	6,911	712	1,212
Chg in cash & cash eq.	129	6	4,460	(3,469)	1,623
Closing cash & cash eq.	1,210	3,942	8,402	4,934	6,556

Per Share

Y/E 31 Mar (Rs)	FY24A	FY25A	FY26E	FY27E	FY28E
Reported EPS	6.1	9.5	15.9	19.1	25.5
Adjusted EPS	6.1	9.7	15.9	19.1	25.5
Dividend per share	1.5	1.5	1.5	1.5	1.5
Book value per share	90.9	98.3	157.4	175.1	199.1

Valuations Ratios

Y/E 31 Mar (x)	FY24A	FY25A	FY26E	FY27E	FY28E
EV/Sales	4.3	3.6	2.9	2.1	1.5
EV/EBITDA	66.6	41.6	27.5	22.6	15.9
Adjusted P/E	124.0	78.8	47.8	39.8	29.8
P/BV	8.4	7.7	4.8	4.3	3.8

DuPont Analysis

Y/E 31 Mar (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Tax burden (Net profit/PBT)	64.8	71.9	75.4	74.3	74.0
Interest burden (PBT/EBIT)	111.5	96.4	101.0	98.4	94.5
EBIT margin (EBIT/Revenue)	4.8	6.6	8.6	7.8	7.8
Asset turnover (Rev./Avg TA)	4.7	4.7	5.4	4.6	6.5
Leverage (Avg TA/Avg Equity)	0.4	0.5	0.4	0.4	0.4
Adjusted ROAE	6.9	10.2	12.8	11.5	13.6

Ratio Analysis

Y/E 31 Mar	FY24A	FY25A	FY26E	FY27E	FY28E
YoY growth (%)					
Revenue	54.0	20.1	23.6	38.5	38.7
EBITDA	7.7	59.9	51.6	21.4	42.1
Adjusted EPS	(9.0)	57.3	65.1	20.0	33.4
Profitability & Return ratios (%)					
EBITDA margin	6.4	8.5	10.5	9.2	9.4
EBIT margin	4.8	6.6	8.6	7.8	7.8
Adjusted profit margin	3.5	4.5	6.6	5.7	5.5
Adjusted ROAE	6.9	10.2	12.8	11.5	13.6
ROCE	6.6	9.1	11.4	11.3	13.2
Working capital days (days)					
Receivables	108	142	150	140	130
Inventory	116	79	90	85	85
Payables	142	152	150	150	150
Ratios (x)					
Gross asset turnover	4.4	4.1	4.3	4.3	4.8
Current ratio	1.2	1.3	1.8	1.5	1.4
Net interest coverage ratio	3.7	4.2	8.7	7.4	7.9
Adjusted debt/equity	0.4	0.4	0.1	0.1	0.2

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 01 February 2030**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "**MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.